Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical trial for the treatment of NASH; and TERN-201, a vascular adhesion protein-1 inhibitor that is in Phase Ib clinical trial for the treatment of NASH. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase I clinical trial for the treatment of NASH; and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for NASH and metabolic diseases, such as obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.

Terns Pharmaceuticals, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

FOSTER CITY, CALIF., DEC. 09, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THE PRICING OF ITS UPSIZED UNDERWRITTEN PUBLIC OFFERING OF 16,250,000 SHARES OF ITS COMMON STOCK AT A PUBLIC OFFERING PRICE OF $40.00 PER SHARE, BEFORE UNDERWRITING DISCOUNTS AND COMMISSIONS. THE GROSS PROCEEDS FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFERING EXPENSES PAYABLE BY TERNS, ARE EXPECTED TO BE $650 MILLION, EXCLUDING ANY EXERCISE OF THE UNDERWRITERS' OPTION TO PURCHASE ADDITIONAL SHARES. TERNS HAS GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 2,437,500 SHARES OF COMMON STOCK AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS EXPECTED TO CLOSE ON DECEMBER 11, 2025, SUBJECT TO CUSTOMARY CLOSING CONDITIONS. ALL OF THE SECURITIES ARE BEING OFFERED BY TERNS.

TERNS ANNOUNCES PRICING OF UPSIZED $650 MILLION PUBLIC OFFERING

FOSTER CITY, CALIF., DEC. 09, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT IT HAS COMMENCED A PROPOSED UNDERWRITTEN PUBLIC OFFERING OF $400 MILLION OF SHARES OF ITS COMMON STOCK AND, IN LIEU OF COMMON STOCK TO CERTAIN INVESTORS, PRE-FUNDED WARRANTS TO PURCHASE SHARES OF ITS COMMON STOCK. IN ADDITION, TERNS EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL $60 MILLION OF SHARES OF COMMON STOCK OFFERED IN THE PUBLIC OFFERING AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. ALL OF THE SHARES AND PRE-FUNDED WARRANTS TO BE SOLD IN THE OFFERING WILL BE OFFERED BY TERNS. THE OFFERING IS SUBJECT TO MARKET AND OTHER CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

TERNS ANNOUNCES PROPOSED PUBLIC OFFERING

64% MMR ACHIEVEMENT BY 24 WEEKS ACROSS ALL EFFICACY EVALUABLE PATIENTS 75% MMR ACHIEVEMENT BY 24 WEEKS IN EFFICACY EVALUABLE PATIENTS AT DOSES > 320MG QD ENCOURAGING SAFETY/TOLERABILITY PROFILE MAINTAINED WITH LONGER DURATION OF TREATMENT COMPANY TO HOST INVESTOR UPDATE CALL TODAY AT 4:30PM ET FOSTER CITY, CALIF., DEC. 08, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT UPDATED AND EXPANDED DATA FROM THE ONGOING CARDINAL TRIAL OF TERN-701, A NOVEL INVESTIGATIONAL ALLOSTERIC BCR::ABL1 INHIBITOR, IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC MYELOID LEUKEMIA (CML) ARE BEING PRESENTED TODAY AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION TAKING PLACE DECEMBER 6-9, 2025 IN ORLANDO, FL.

TERNS HIGHLIGHTS ADDITIONAL POSITIVE PHASE 1 CLINICAL DATA SUPPORTING TERN-701'S BEST-IN-DISEASE POTENTIAL IN RELAPSED/REFRACTORY CML AT THE 67TH ASH ANNUAL MEETING

FOSTER CITY, CALIF., NOV. 14, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT MEMBERS OF SENIOR MANAGEMENT WILL BE PRESENTING AT THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON ON MONDAY, NOVEMBER 17, 2025 AT 4:30 P.M.

TERNS PHARMACEUTICALS TO PARTICIPATE IN THE JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON

UNPRECEDENTED PHASE 1 CML EFFICACY DATA AND POTENTIAL BEST-IN-DISEASE PROFILE OF TERN-701 FEATURED IN ASH 2025 ABSTRACT UPCOMING ASH ORAL PRESENTATION TO FEATURE EXPANDED AND UPDATED DATASET FROM CARDINAL TRIAL CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $295 MILLION, EXPECTED TO PROVIDE RUNWAY INTO 2028 FOSTER CITY, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED CORPORATE UPDATES.

TERNS PHARMACEUTICALS REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

FOSTER CITY, CALIF., NOV. 04, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT IT HAS GRANTED AS OF NOVEMBER 1, 2025 EQUITY INDUCEMENT AWARDS TO TWO NEW EMPLOYEES UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN, AS AMENDED. THE EQUITY AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE MADE AS A MATERIAL INDUCEMENT TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH TERNS.

TERNS PHARMACEUTICALS REPORTS INDUCEMENT GRANTS TO NEW EMPLOYEES UNDER NASDAQ LISTING RULE 5635(C)(4)

UNPRECEDENTED PHASE 1 CML EFFICACY DATA WITH 64% MMR ACHIEVEMENT BY 24 WEEKS IN A REFRACTORY PATIENT POPULATION ENCOURAGING SAFETY AND TOLERABILITY PROFILE AT ALL DOSES EVALUATED COMPANY TO HOST INVESTOR UPDATE CALL ON DECEMBER 8 TH AT 4:30PM ET FOSTER CITY, CALIF., NOV. 03, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL STAGE ONCOLOGY COMPANY, TODAY ANNOUNCED THAT DATA FROM THE ONGOING CARDINAL TRIAL OF TERN-701, A NOVEL INVESTIGATIONAL ALLOSTERIC BCR::ABL1 INHIBITOR, IN PARTICIPANTS WITH PREVIOUSLY TREATED CHRONIC MYELOID LEUKEMIA (CML) HAS BEEN SELECTED FOR ORAL PRESENTATION ON DECEMBER 8, 2025 AT THE 67TH AMERICAN SOCIETY OF HEMATOLOGY (ASH) ANNUAL MEETING AND EXPOSITION TAKING PLACE IN ORLANDO, FL.

TERNS ANNOUNCES ABSTRACT WITH POSITIVE CLINICAL DATA FOR TERN-701 IN RELAPSED/REFRACTORY CML SELECTED FOR ORAL PRESENTATION AT 67TH ASH ANNUAL MEETING

RESULTS SHOW MAXIMUM PLACEBO-ADJUSTED WEIGHT LOSS OF 4.6% WITH 12% TREATMENT DISCONTINUATION DUE TO ADVERSE EVENTS ASYMPTOMATIC, REVERSIBLE GRADE 3 LIVER ENZYME ELEVATIONS OCCURRED IN THREE PARTICIPANTS DURING POST-TREATMENT FOLLOW-UP PERIOD, TWO OF WHICH WERE DEEMED DRUG RELATED COMPANY WILL NOT ADVANCE TERN-601 OR INVEST IN OTHER METABOLIC ASSETS REITERATES FOCUS ON TERN-701, A POTENTIAL BEST-IN-CLASS ALLOSTERIC BCR-ABL INHIBITOR, FOR CHRONIC MYELOID LEUKEMIA WITH CLINICAL DATA THIS QUARTER FOSTER CITY, CALIF., OCT. 21, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A PORTFOLIO OF SMALL-MOLECULE PRODUCT CANDIDATES TO ADDRESS SERIOUS DISEASES, INCLUDING ONCOLOGY AND OBESITY, TODAY ANNOUNCED TOPLINE 12-WEEK RESULTS FROM ITS PHASE 2 TRIAL OF TERN-601, A NOVEL, ONCE-DAILY, ORAL GLP-1 RECEPTOR AGONIST (GLP-1RA) AS A POTENTIAL TREATMENT FOR OBESITY.

TERNS PHARMACEUTICALS REPORTS TOPLINE 12-WEEK DATA FROM ITS PHASE 2TRIAL EVALUATING ORAL GLP-1 RECEPTOR AGONIST TERN-601 IN OBESITY

FOSTER CITY, CALIF., OCT. 02, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A PORTFOLIO OF SMALL-MOLECULE PRODUCT CANDIDATES TO ADDRESS SERIOUS DISEASES, INCLUDING ONCOLOGY AND OBESITY, TODAY ANNOUNCED THAT IT HAS GRANTED AS OF OCTOBER 1, 2025 EQUITY INDUCEMENT AWARDS TO FOUR NEW EMPLOYEES UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN, AS AMENDED. THE EQUITY AWARDS WERE APPROVED BY THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS IN ACCORDANCE WITH NASDAQ LISTING RULE 5635(C)(4) AND WERE MADE AS A MATERIAL INDUCEMENT TO THE EMPLOYEES' ACCEPTANCE OF EMPLOYMENT WITH TERNS.

FOSTER CITY, CALIF., AUG. 21, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A PORTFOLIO OF SMALL-MOLECULE PRODUCT CANDIDATES TO ADDRESS SERIOUS DISEASES, INCLUDING ONCOLOGY AND OBESITY, TODAY ANNOUNCED IT WILL HOST AN INVESTOR EDUCATIONAL WEBINAR ON TERN-701 IN ADVANCE OF THE DATA RELEASE EXPECTED IN FOURTH QUARTER OF 2025.

TERNS PHARMACEUTICALS TO HOST AN EDUCATIONAL WEBINAR ON TERN-701 FOR INVESTORS IN ADVANCE OF PHASE 1 DATA EXPECTED IN FOURTH QUARTER 2025

PHASE 1 TRIAL OF TERN-701 IN CHRONIC MYELOID LEUKEMIA (CML) ENROLLING WELL; EFFICACY AND SAFETY DATA INCLUDING 6-MONTH MAJOR MOLECULAR RESPONSE (MMR) RATES EXPECTED IN 4Q25

TERNS PHARMACEUTICALS REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATES

FOSTER CITY, CALIF., AUG. 04, 2025 (GLOBE NEWSWIRE) -- TERNS PHARMACEUTICALS, INC. (TERNS OR THE COMPANY) (NASDAQ: TERN), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING A PORTFOLIO OF SMALL-MOLECULE PRODUCT CANDIDATES TO ADDRESS SERIOUS DISEASES, INCLUDING ONCOLOGY AND OBESITY, TODAY ANNOUNCED THAT IT HAS GRANTED AS OF AUGUST 1, 2025 EQUITY INDUCEMENT AWARDS TO TWO NEW EMPLOYEES UNDER THE TERMS OF THE 2022 EMPLOYMENT INDUCEMENT AWARD PLAN, AS AMENDED.

PHASE 1 CLINICAL STUDY OF TERN-601 DEMONSTRATED DIFFERENTIATED PROFILE IN 28-DAY STUDY; TOPLINE DATA WERE PRESENTED IN SEPTEMBER 2024

TERNS PHARMACEUTICALS PRESENTS POSITIVE DATA FROM PHASE 1 STUDY OF TERN-601 ONCE-DAILY ORAL GLP-1R AGONIST FOR TREATMENT OF OBESITY AT 85TH ANNUAL AMERICAN DIABETES ASSOCIATION SCIENTIFIC SESSIONS

Terns Pharmaceuticals, Inc.

TERN

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Terns Pharmaceuticals, Inc.

TERN.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

TERN